PlantForm Corporation is a Canadian biotech company with a low-cost, proprietary manufacturing platform for a wide range of plant-made pharmaceuticals, including monoclonal antibodies, therapeutic proteins and vaccines for the treatment of cancer, HIV/AIDS, Ebola virus and other life-threatening illnesses. The company’s vivoXPRESS® technology uses genetically modified tobacco plants to ‘grow’ biopharmaceuticals in fully contained greenhouse environments. PlantForm’s pipeline features both innovator and biosimilar products, including: • 3 biosimilar cancer drugs, leading with trastuzumab, a plant-produced version of the breast cancer drug Herceptin® • innovator antibodies for HIV/AIDS, funded by the Government of Canada and the Bill & Melinda Gates Foundation • innovator antibodies for treatment of Ebola virus (Sudan strain), with financial support from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) and in collaboration with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) • recombinant butyrylcholinesterase (BuChE), an enzyme used as preventative medicine for people vulnerable to attack by nerve agents, organophosphates or other stimulants. PlantForm is interested in establishing partnerships with other companies to develop additional targeted biosimilar and innovator drugs.